Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian DDI with Midazolam and Oral Contraceptives in Healthy Females
NCT05706753Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of milvexian in thrombosis, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of Midazolam and 1-hydroxymidzolam, Area Under the Plasma Concentration-time Curve from Time 0 to Time of the Last Observed Quantifiable Concentration of Midazolam and 1-hydroxymidzolam and 4 more. Started Jan 2023; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT05706753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05706753.